Skip to main content

Table 2 Association between SLC6A2 genotypes and response to MPH treatment according to the CGI-I

From: Possible association of norepinephrine transporter -3081(A/T) polymorphism with methylphenidate response in attention deficit hyperactivity disorder

  

Response to MPH by CGI-I

N (% within SLC6A2 genotype)

  
 

SLC6A2 genotype

Poor

(CGI-I: 3-7)

Good

(CGI-I: 1 or 2)

Total

(% within total number)

p-value

-3081(A/T) polymorphism

A/A

18 (62.1%)

11 (37.9%)

29 (25.9%)

0.08

 

A/T

24 (40.0%)

36 (60.0%)

60 (53.6%)

 
 

T/T

8 (34.8%)

15 (65.2%)

23 (20.5%)

 
 

A/A

18 (62.1%)

11 (37.9%)

29 (25.9%)

0.03

 

A/T+T/T

32 (38.6%)

51 (61.4%)

83 (74.1%)

 
 

Total

50 (44.6%)

62 (55.4%)

112

 

G1287A polymorphism

G/G

22 (37.9%)

36 (62.1%)

58 (51.8%)

0.12

 

G/A

24 (57.9%)

18 (42.9%)

42 (37.5%)

 
 

A/A

4 (33.3%)

8 (66.7%)

12 (10.7%)

 
 

G/G

22 (37.9%)

36 (62.1%)

58 (51.8%)

0.14

 

G/A+A/A

28 (51.9%)

26 (48.1%)

54 (48.2%)

 
 

Total

50 (44.6%)

62 (55.4%)

112

Â